Get notified when PFE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure Of Cfo (new) — CFO transition disclosed on same date as this 8-K filing, indicating sudden leadership change in critical financial role.
Pfizer CFO transition disclosed; company reaffirms FY2026 guidance of $59.5-$62.5B revenue
Filed June 18, 2026 · Period ending June 18, 2026 · ~1 min read
Key Changes
-
high
Pfizer announced a Chief Financial Officer transition on June 18, 2026, the same day as this filing, representing a key leadership change at the pharmaceutical giant.
Item 7.01 — Regulation FD Disclosure verify on EDGAR → -
high
Company reaffirmed full-year 2026 guidance: revenues of $59.5-$62.5 billion and adjusted diluted EPS of $2.80-$3.00, unchanged from December 2025 introduction and May 2026 reaffirmation.
Item 7.01 — Regulation FD Disclosure verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SNOA 10-K) is open in full — no account needed.
Partner
Trade PFE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 18, 2026 1:35 PM